RxDoctor Payments Data

Judith Andreano, MD

Dermatology · Strongsville, OHNPI 1316939911

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $108,494 of the $151,834 with a category attached, or 71.5%. 40 manufacturers reported payments, led by Amgen at 58.6% of the total. Among dermatology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$151,834in general payments, 2019–2025

Across 1,526 payments — averaging $99.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$89K
  • Almirall LLC$18K
  • Bristol Myers Squibb$10K
  • AbbVie$4K
  • Journey Medical Corporation$3K
  • Johnson & Johnson$3K
  • plus $24K from 34 others

What the payments were for

  • Consulting fees$6,1184%
  • Speaking & faculty fees$108,49471%
  • Travel & lodging$5,2153%
  • Food & beverage$31,43021%
  • Education$5760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$151,834 in reported general payments places this provider in the 95th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$286,942
Medicare patients
1,233
Services billed
4,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast64$294,869
Humira(Cf) PenAdalimumab27$272,646
Dupixent PenDupilumab49$178,870
TremfyaGuselkumab13$178,316
Taltz AutoinjectorIxekizumab14$90,861
Clobetasol Propionate153$7,231
Fluocinonide136$7,089
Ketoconazole366$5,763
Clindamycin Phosphate68$4,165
Calcipotriene14$4,067
Metronidazole67$3,397
Doxycycline Hyclate155$3,158
Triamcinolone Acetonide229$2,684
Ivermectin16$2,448
Mometasone Furoate110$1,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$89,015$294,86964 claims
Johnson & JohnsonTremfya$3,262$178,31613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 460 dermatology providers in Ohio.

Other dermatology in Strongsville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →